Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

NCT03436199 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

558

Enrollment

INDUSTRY

Sponsor class

Conditions

Walking Impairment
Multiple Sclerosis

Interventions

DRUG: ADS-5102, 137 mg
DRUG: ADS-5102, 274 mg
OTHER: Placebo

Sponsor

Adamas Pharmaceuticals, Inc.